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OBJECTIVE: Assess types and inﬂuence of health beneﬁt limits
on treatment of psoriasis and other dermatological conditions.
METHODS: Five major health insurance providers in the United
States, Kaiser, Foundation Health Plan, United Health Group,
CIGNA Corp, Aetna Inc, and AFLAC Inc. were contacted for
information regarding their health beneﬁt limits. Annual costs of
drugs were obtained from the Drug Topics Red Book 2003 for
a 70-kg participant. Age at which insurance beneﬁts would
exhaust was calculated based on different onset ages for treat-
ment costing $30,000/year and different lifetime beneﬁt limit
amounts. RESULTS: Various forms of health beneﬁt limits were
imposed by insurance companies. These companies paid a
limited amount for drugs annually, with annual caps ranging
from $1000 to $20,000. Companies had different payment poli-
cies for brand-name drugs and generic drugs. Lifetime beneﬁt
maximum for physician ofﬁce and hospital visit expenses was
another form of cap that was used. Assuming no other claims
applied, analysis indicated that a lifetime beneﬁt cap of $500,000
for treatment of psoriasis starting at age 20 years exhausted
around the age of 40 years. Furthermore, an annual cap of $1000
allowed for full coverage of only methotrexate while, annual
caps of $15,000 or less affected coverage for etanercept and efal-
izumab. For patients requiring multiple drug treatments, even
higher annual caps limited drug coverage. CONCLUSIONS:
Annual and lifetime limits were most common form of caps.
Insurance limits potentially affect access to health care as they
limit coverage of treatments for psoriasis and potentially other
conditions. It is important for physicians to be aware of the vari-
ations in insurance coverage, especially before a new treatment
option is explored. If insurance coverage was a standard ques-
tion in the doctor-patient encounter, it could arguably improve
patient compliance and outcomes.
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OBJECTIVES: Comparing relationships between health status
and costs and medication related factors in the treatment of acne
and psoriasis. METHODS: This was a cross sectional study com-
paring cohorts of acne and psoriasis patients, using the United
States Medical Expenditure Panel Survey (MEPS) 2000 database.
Patients were identiﬁed using the ICD-9 (International Classiﬁ-
cation of Diseases, 9th revision) code “706” for acne vulgaris
and “696” for psoriasis and similar conditions. ICD-9 codes for
acne/psoriasis and receipt of medication for acne/psoriasis were
used in obtaining records of medical events. Costs, demograph-
ics information, health care service utilization and clinical patient
variables were retrieved from the MEPS database. Health status
information was obtained using the EuroQOL (EQ-5D) scores
available in MEPS. Indices for medication adherence and comor-
bidities were also calculated using the data from the MEPS. Sep-
arate weighted multivariate linear regression analysis was
performed on data for approximately 5 million acne patients and
1 million psoriasis patients (weighted sample size). RESULTS:
Acne-related medication accounted for approximately 36% of
the total acne related health care costs, while psoriasis-related
medications accounted for almost 50% of the total psoriasis
related health care costs. Both acne and psoriasis patients had
an average of almost 3 annual prescription reﬁlls. Use of topical
corticosteroid therapy was associated with decrease in psoriasis-
speciﬁc health care costs (p = 0.022) and better health status (P
< 0.01). Increased ofﬁce based visits resulted in higher acne and
psoriasis related health care costs (p < 0.01). Increased number
of reﬁlls of acne speciﬁc drugs and oral contraceptive use was
associated with an improvement in health status (p < 0.05).
CONCLUSIONS: Use of controller medications in psoriasis,
most notably topical corticosteroids is the primary driver of
reduced health care costs and better health status. Contrary to
popular belief, pharmacological treatment of acne does not sig-
niﬁcantly add to acne-related health care costs.
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OBJECTIVES: This study examined if patients with severe pso-
riasis were treated in accordance with therapy/medications as per
guidelines recommended by the American Academy of Derma-
tology (AAD) (i.e. receive either phototherapy or systemic treat-
ment). METHODS: A survey for this study was conducted by
the National Psoriasis Foundation between November and
December 2004. Respondents, screened for a mix of gender and
age, were interviewed over the phone (n = 188) and by online
surveys (n = 212). Information on current medication use was
obtained. Self-reported Body Surface Area (BSA) involvement
was used to measure severity of psoriasis. BSA of greater than
10% is indicative of severe psoriasis. Severity was also assessed
more globally using the Koo-Mentor Psoriasis Index (KMPI).
KMPI scores of 50 and above are suggestive of signiﬁcant nega-
tive health related quality of life and warrant initiation of sys-
temic therapy. Cross sectional nature of this study permitted
analysis of patients with severe psoriasis only. Descriptive data
were generated to determine demographic characteristics of
study population and prescription patterns. RESULTS: Approx-
imately 55% of the population had severe psoriasis as measured
by BSA, while 75% had severe psoriasis as per KMPI scores.
About 19% of the study population indicated that they were cur-
rently not on any treatment. Almost 15% of the patients with
severe psoriasis identiﬁed with BSA (n = 212) and KMPI (n =
299) were on some form of topical therapy alone to treat their
psoriasis (i.e. they were not treated in accordance to the AAD
guidelines.). CONCLUSIONS: AAD guidelines provide a stan-
dard for psoriasis treatment options and conditions for their pre-
scriptions. Even with such easily accessible guidelines in place,
this study has shown that there are several people suffering from
severe psoriasis that are not on recommended therapy.
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